|
|
|
Education:
|
|
2025
|
Habilitation in Physiology and Pathophysiology, Medical University of Graz, Austria
|
|
2023
|
Open Innovation Course, Harvard Business School, USA
|
|
2010 –2014
|
PhD thesis at the Medical University of Graz – Ludwig Boltzmann Institute for Lung Vascular Research,
Graz, Austria
|
|
2008 –2010
|
Master Degree in Medical Biotechnology at the University of Trieste, Italy
|
|
Positions:
|
|
2025 – present
|
1st Deputy Speaker of Division of Physiology and Pathophysiology, Medical University of Graz, Austria
|
|
2024 – present
|
Associate Faculty Member at the Medical University of Graz, Austria
|
|
2023
|
Research Unit Leader of Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria
|
|
2022 – present
|
Head of the research unit "Metabolic and hormonal influences on the fate of mesenchymal cells in chronic lung diseases"
|
|
2022 – present
|
Senior Scientist at the Division of Physiology and Pathophysiology, Medical University of Graz, Austria
|
|
2019 – 2021
|
Post-Doctoral trainee, Endocrinology and Diabetology Department, Medical University of Graz, Austria
|
|
2015 – 2018
|
Post-Doctoral trainee, Ludwig Boltzmann Institute for Lung Vascular Research, Medical University of Graz, Austria
|
|
Career breaks:
|
|
2018 – 2019
|
1st career break: maternity leave
|
|
2021 – 2022
|
2nd career break: maternity leave
|
|
Significant research achievements and awards (10 most important):
|
- Project funding: INHalation of ALOXistatin against IPF – INALOX. ERDERA's first Joint
Transnational Call (JTC 2025) (280,000 €; 2025 – 2028)
- Project funding: European Respiratory Society Long Term Fellowship at
Prof. Uroš Maver Laboratory (Institute of Biomedical Sciences, University of Maribor)
– Development of an advanced in vitro lung model for pulmonary
fibrosis research (2026 – 2027).
- Project funding: The influence of adipsin in lung fibroblasts phenotype. Stadt Graz funding
FIF-A 16-1130/2024-0001t-2025 (9,000 €)
- Leader of Working Group 1 on the COST-EU Action Sex as a Biological Variable (SABV CA24168)
(2025 – 2028)
- Project funding: SCIENCE4ALL – Patient and Public Involvement and Engagement Implementation
(PPIE) CALL 2020 – 2021 (60,000 €; 2021 – 2023)
- Project funding: Hertha Firnberg Program – Austrian Science Fund (FWF) – Role of
sclerostin in pulmonary hypertension (270,000 €; 2019)
- Organization for the Study of Sex Differences (OSSD), Bergen, Norway, Best Poster Prize
(PhD Student: Pamela Waked)
- DACH Symposium Pulmonale Hypertonie, 2015: 1st Prize Best Poster
- Michael Neumann Prize 2015, Outstanding Publication
- American Thoracic Society Travel Grant 2013, Philadelphia, USA: ATS Conference
|